New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2009-05-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm900148cPMID 19432421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure of a β1-adrenergic G-protein-coupled receptor

  2008cited by this paper
• Three‐dimensional model of the human urotensin‐II receptor: Docking of human urotensin‐II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model

  2008cited by this paper
• Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II.

  2008cited by this paper
• The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist

  2008cited by this paper
• Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.

  2008cited by this paper
• Structure–activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11)

  2008cited by this paper
• A semiempirical free energy force field with charge‐based desolvation

  2007cited by this paper
• High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

  2007cited by this paper
• High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor

  2007cited by this paper
• Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

  2007cited by this paper
• In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4–11) (UFP‐803)

  2006cited by this paper
• Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide.

  2006cited by this paper
• Urotensin-II receptor antagonists.

  2006cited by this paper
• Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord.

  2005cited by this paper
• Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells

  2005cited by this paper
• Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.

  2005cited by this paper
• Urotensin-II receptor ligands. From agonist to antagonist activity.

  2005cited by this paper
• Structure–activity relationship study on human urotensin II

  2005cited by this paper
• Unraveling the active conformation of urotensin II.

  2004cited by this paper
• Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents.

  2004cited by this paper
• UCSF Chimera—A visualization system for exploratory research and analysis

  2004cited by this paper
• Structure-activity relationships and structural conformation of a novel urotensin II-related peptide.

  2004cited by this paper
• Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.

  2004cited by this paper
• Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.

  2004cited by this paper
• Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas.

  2004cited by this paper
• Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.

  2003cited by this paper
• Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay

  2003cited by this paper
• Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

  2003cited by this paper
• Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction

  2003cited by this paper
• Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

  2003cited by this paper
• Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta

  2003cited by this paper
• Structural requirements at the N-terminus of urotensin II octapeptides.

  2002cited by this paper
• Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model.

  2002cited by this paper
• A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.

  2002cited by this paper
• Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord.

  2002cited by this paper
• Is urotensin‐II the new endothelin?

  2002cited by this paper
• Designing peptide receptor agonists and antagonists

  2002cited by this paper
• Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey

  2002cited by this paper
• Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

  2002cited by this paper
• Crystal structure of rhodopsin: A G protein-coupled receptor.

  2000cited by this paper
• Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

  2000cited by this paper
• Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).

  1999cited by this paper
• Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.

  1998cited by this paper
• Torsion angle dynamics for NMR structure calculation with the new program DYANA.

  1997cited by this paper
• MOLMOL: a program for display and analysis of macromolecular structures.

  1996cited by this paper
• Automated docking of flexible ligands: Applications of autodock

  1996cited by this paper
• Urotensin II in the central nervous system of the frog Rana ridibunda: immunohistochemical localization and biochemical characterization

  1996cited by this paper
• The program XEASY for computer-supported NMR spectral analysis of biological macromolecules

  1995cited by this paper
• Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients

  1995cited by this paper
• optymization of disulfidel bont formation

  1994cited by this paper
• New evidence for a membrane-bound pathway in hormone receptor binding.

  1993cited by this paper
• PROCHECK: a program to check the stereochemical quality of protein structures

  1993cited by this paper
• Stereochemical quality of protein structure coordinates

  1992cited by this paper
• Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda.

  1992cited by this paper
• Functional receptors for fish neuropeptide urotensin II in major rat arteries.

  1988cited by this paper
• Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces.

  1988cited by this paper
• NMR of proteins and nucleic acids

  1988cited by this paper
• Membrane lipid phase as catalyst for peptide-receptor interactions.

  1986cited by this paper
• Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy

  1983cited by this paper
• Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins.

  1983cited by this paper
• A two-dimensional nuclear overhauser experiment with pure absorption phase in four quadrants☆

  1982cited by this paper
• Multiple quantum filters for elucidating NMR coupling networks

  1982cited by this paper
• Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes.

  1980cited by this paper
• Investigation of exchange processes by two‐dimensional NMR spectroscopy

  1979cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Structural insights into hormone recognition and G-protein coupling of the urotensin-II receptor

  2025cites this paper
• Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators.

  2024cites this paper
• Identification of Mortalin as the Main Interactor of Mycalin A, a Poly-Brominated C-15 Acetogenin Sponge Metabolite, by MS-Based Proteomics

  2024cites this paper
• Towards Targeting the Urotensinergic System: Overview and Challenges.

  2019cites this paper
• Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue.

  2018cites this paper
• Efficacy of Urotensin II in Cardiovascular System

  2018cites this paper
• Synthèse en phase solide de pyrrolo[3,2-e][1,4]diazépin-2-ones modulateurs du système urotensinergétique

  2017cites this paper
• Insight into the role of urotensin II‐related peptide tyrosine residue in UT activation

  2017cites this paper
• Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II.

  2017cites this paper
• Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.

  2016cites this paper
• Structure–Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position 9

  2016cites this paper
• An investigation into the origin of the biased agonism associated with the urotensin II receptor activation

  2015cites this paper
• NMR spectroscopy: a useful tool for drugs development and monitoring biological reactions

  2015cites this paper
• De Novo Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolodiazepin-2-one γ-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction ex Vivo.

  2015cites this paper
• International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

  2015cites this paper
• Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.

  2014cites this paper
• A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands

  2014cites this paper
• Urantide Conformation and Interaction with the Urotensin‐II Receptor

  2014cites this paper
• Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion

  2014cites this paper
• Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.

  2014cites this paper
• New insight into the binding mode of peptides at urotensin‐II receptor by Trp‐constrained analogues of P5U and urantide

  2013cites this paper
• Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.

  2013influential citation
• Optimization of isochromanone based urotensin II receptor agonists.

  2010cites this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cites this paper
• Update 1 of: Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure.

  2010cites this paper
• Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors.

  2010cites this paper
• GSK1562590, a slowly dissociating urotensin‐II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo

  2010cites this paper